Indication intelligence, analysis and sector perception

Kite Pharma (KITE) clinical collaboration with Roche Holdings’ (RHHBY) Genentech

March 17, 2016 10:16am

To combine its KTE-C19 CAR T therapy with anti-PDL1 Atezolizumab in Non-Hodgkin Lymphoma

KITE and initiated a clinical trial collaboration with Genentech, a member of the Roche Group (RHHBY), to evaluate the safety and efficacy of KTE-C19, in combination with Atezolizumab (also known as MPDL3280A), in patients with refractory, aggressive non-Hodgkin lymphoma (NHL).

Atezolizumab is an investigational monoclonal antibody designed to target and bind to a protein called PD-L1, which is expressed on tumor cells and tumor-infiltrating immune cells.

The Bottom Line: A multi-center P1b/2 study is expected to begin in 2016. The study will use the same KTE-C19 dose and regimen as Kite's ongoing, potential registration study (ZUMA-1) in patients with refractory, aggressive NHL. Kite will be the sponsor of the study, and the results will be used to evaluate options for further development of the combination.

KITE closed at $44.13 and is DOWN -$1.01 <-2.30%> at the open to $43.12. Contrary to the market, I believe this is a positive as to collaboration with a large pharma for NHL patients in time.

BUY

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

2 hours 1 min ago
RegMed Investors’ (RMi) pre-open: market, market and the sector pullbacks are driven by Israel retaliation against Iran tempered expectations for a rate cut

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.